Science & Enterprise subscription

Follow us on Twitter

  • Wish it weren't needed, but ... https://t.co/SZAb2GO2vz
    about 2 days ago
  • The Edelman public relations agency released results of a survey earlier this month gauging the public's awareness… https://t.co/XaxxGJOYQl
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Public, Tech Execs Differ on A.I. Use https://t.co/cvVj3IyCR0 #Science #Business
    about 2 days ago
  • New contributed post on Science and Enterprise: https://t.co/VdSFcTR4CY Keeping Information Safe in the Internet Age
    about 2 days ago
  • Engineers in Germany designed screens for mobile phones and tablets that not only feel touch pressure, but can also… https://t.co/9mdOPeevI1
    about 3 days ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Biomarker Diagnostics Company Gains $40M in Venture Funding

Loose bills of multiple denominations (borman818)Astute Medical Inc. in San Diego, a developer of biomarker-based medical diagnostics, says it completed $40.4 million in series C venture financing, the third cycle of funding after initial start-up. The funding round was led by MPM Capital and included new investor Kaiser Permanente Ventures, as well as existing investors De Novo Ventures, Delphi Ventures, Domain Associates, and Johnson & Johnson Development Corporation.

Astute Medical identifies and validates protein biomarkers that can be used for diagnosing diseases, particularly with labratory (in vitro) tests. The company’s current interests include tests involving abdominal pains, acute coronary syndromes, cerebrovascular injury (e.g., stroke), kidney injury, and sepsis.

The company plans to use the proceeds from the round to begin commercializing its first product, as well as advance and expand its research, development, and validation of biomarker-based lab tests. Details about its first commercial product were not disclosed.

Astute Medical was founded in 2007 by former executives in the diagnostics company Biosite Inc.  The company completed its series A funding round in May 2008, with $6.2 million led by DeNovo Ventures. Its series B round, was divided into two segments: $26.5 million in May 2010, and $13 million in March 2011.

Read more:

Hat tip: Fortune/Term Sheet

Photo: borman818/Flickr

*     *     *

Please share Science & Enterprise ...

Comments are closed.